Search: onr:"swepub:oai:lup.lub.lu.se:78f8c9e1-3b92-4677-a542-20c86d4eec24" > Health-related qual...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05781naa a2200661 4500 | |
001 | oai:lup.lub.lu.se:78f8c9e1-3b92-4677-a542-20c86d4eec24 | |
003 | SwePub | |
008 | 201222s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/78f8c9e1-3b92-4677-a542-20c86d4eec242 URI |
024 | 7 | a https://doi.org/10.3324/haematol.2019.2222992 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Nielsen, Lene Kongsgaardu Odense University Hospital4 aut |
245 | 1 0 | a Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression : A prospective, open-label, multicenter, randomized, phase 3 study |
264 | c 2019-09-12 | |
264 | 1 | b Ferrata Storti Foundation (Haematologica),c 2020 |
300 | a 10 s. | |
520 | a Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multiple myeloma, comparing melphalan-prednisolone in combination with thalidomide or lenalidomide, followed by maintenance therapy until progression (MPT-T or MPR-R). The EORTC QLQ-C30 and MY20 questionnaires were completed at baseline, after three and nine induction cycles and six and 12 months of maintenance therapy. Linear mixed models and minimal important differences were used for evaluation. 596 patients participated in HRQoL reporting. Patients reported clinically relevant improvement in global quality of life (QoL), future perspective and role and emotional functioning, and less fatigue and pain in both arms. The latter being of large effect size. In general, improvement occurred after 6-12 months of maintenance only and was independent of the World Health Organisation performance at baseline. Patients treated with MPR-R reported clinically relevant worsening of diarrhea, and patients treated with MPT-T reported a higher incidence of neuropathy. Patients who remained on lenalidomide maintenance therapy for at least three months reported clinically meaningful improvement in global QoL and role functioning at six months, remaining stable thereafter. There were no clinically meaningful deteriorations, but patients on thalidomide reported clinically relevant worsening in neuropathy. In general, HRQoL improves both during induction and maintenance therapy with immunomodulatory drugs. The side effect profile of treatment did not negatively affect global QoL, but it was, however, clinically relevant for the patients. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Stege, Claudiau Vrije Universiteit Amsterdam4 aut |
700 | 1 | a Lissenberg-Witte, Birgitu Vrije Universiteit Amsterdam4 aut |
700 | 1 | a Der Holt, Bronno Vanu Erasmus University Medical Center4 aut |
700 | 1 | a Mellqvist, Ulf Henriku Sahlgrenska University Hospital4 aut |
700 | 1 | a Salomo, Mortenu Copenhagen University Hospital4 aut |
700 | 1 | a Bos, Gerardu Yukioka Hospital4 aut |
700 | 1 | a Levin, Mark David4 aut |
700 | 1 | a Visser-Wisselaar, Heleenu Erasmus University Medical Center4 aut |
700 | 1 | a Hansson, Markusu Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Myelomgruppen,Forskargrupper vid Lunds universitet,WCMM- Wallenberg center för molekylär medicinsk forskning,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Myeloma research group,Lund University Research Groups,WCMM-Wallenberg Centre for Molecular Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital4 aut0 (Swepub:lu)hema-mha |
700 | 1 | a Der Velden, Annette Vanu Martini Hospital, Groningen4 aut |
700 | 1 | a Deenik, Wendy4 aut |
700 | 1 | a Coenen, Juleonu Maastricht University Medical Centre4 aut |
700 | 1 | a Hinge, Majau Vejle Hospital4 aut |
700 | 1 | a Klein, Saskiau Meander Medical Center4 aut |
700 | 1 | a Tanis, Bea4 aut |
700 | 1 | a Szatkowski, Damian4 aut |
700 | 1 | a Brouwer, Rolfu Reinier de Graaf Hospital - SSDZ4 aut |
700 | 1 | a Westerman, Matthijs4 aut |
700 | 1 | a Leys, Rineke4 aut |
700 | 1 | a Sinnige, Harmu Jeroen Bosch Hospital4 aut |
700 | 1 | a Haukås, Einaru Stavanger University Hospital4 aut |
700 | 1 | a Der Hem, Klaas Van4 aut |
700 | 1 | a Durian, Marc4 aut |
700 | 1 | a Gimsing, Peteru Copenhagen University Hospital4 aut |
700 | 1 | a De Donk, Niels Vanu Vrije Universiteit Amsterdam4 aut |
700 | 1 | a Sonneveld, Pieteru Erasmus University Medical Center4 aut |
700 | 1 | a Waage, Andersu St. Olav’s University Hospital4 aut |
700 | 1 | a Abildgaard, Nielsu Odense University Hospital4 aut |
700 | 1 | a Zweegman, Sonjau Vrije Universiteit Amsterdam4 aut |
710 | 2 | a Odense University Hospitalb Vrije Universiteit Amsterdam4 org |
773 | 0 | t Haematologicad : Ferrata Storti Foundation (Haematologica)g 105:6, s. 1650-1659q 105:6<1650-1659x 0390-6078x 1592-8721 |
856 | 4 | u http://dx.doi.org/10.3324/haematol.2019.222299x freey FULLTEXT |
856 | 4 | u https://haematologica.org/article/download/9441/69046 |
856 | 4 8 | u https://lup.lub.lu.se/record/78f8c9e1-3b92-4677-a542-20c86d4eec24 |
856 | 4 8 | u https://doi.org/10.3324/haematol.2019.222299 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view